PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS
ID: 75N95024R00003Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIDABethesda, MD, 20892, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH (AN11)

Original Source

https://sam.gov/opp/f34d61b358c8403aa3e9e51f3c4a07c7/view
Timeline
    Description

    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), is seeking proposals for the "Preparation and Distribution of Research Drug Products" under solicitation number 75N95024R00003. The primary objective of this procurement is to acquire, analyze, create, and distribute a variety of drug compounds essential for drug abuse and addiction research, including controlled and uncontrolled substances, while ensuring compliance with DEA regulations. This contract, structured as an indefinite delivery, indefinite quantity (IDIQ) agreement for a five-year period, aims to enhance research capabilities in the field of drug abuse, with proposals due by November 15, 2024, at 1:00 PM (Eastern Time). Interested parties should contact Scott Duernberger at scott.duernberger@nih.gov or Josh Lazarus at josh.lazarus@nih.gov for further information.

    Files
    Title
    Posted
    Amendment 01.pdf
    The document is an amendment to solicitation 75N95024R00003, issued by the National Institute on Drug Abuse (NIDA). It primarily serves to respond to questions raised by potential offerors regarding proposal requirements. The amendment clarifies that the Technical Proposal is limited to 200 pages, excluding specific introductory and supplementary elements. The document also confirms that a certification for cost or pricing data is not necessary due to expected price competition and specifies that all mandatory qualification criteria must be met upon receipt of the Technical Proposals. A critical detail includes the requirement that offerors must demonstrate access to a DEA-approved secure storage facility for refrigeration of an inventory of around 300 stock items at the time of submission. The proposal due date remains unchanged, set for November 5, 2024. This document emphasizes transparency in the federal procurement process while ensuring compliance with regulatory requirements necessary for contract bidding.
    Amendment 02.pdf
    The document is an amendment to a solicitation by the National Institute on Drug Abuse (NIDA) regarding a Request for Proposals (RFP) referenced as 75N95024R00003. Its primary purpose is to correct the due date for proposals, which remains unchanged as November 15th, 2024, at 1:00 PM (Eastern Time). The amendment outlines the procedures for potential offerors to acknowledge receipt of this change and emphasizes that all other terms and conditions of the solicitation remain intact. It is critical for respondents to confirm their understanding of the amendment, either through their proposals or via separate communication. The document reiterates the need for timely acknowledgment to avoid any potential rejection of offers. Overall, this amendment serves to clarify administrative aspects of the RFP process while ensuring compliance with procurement protocols.
    Solicitation_75N95024R00003_F.pdf
    The National Institute on Drug Abuse (NIDA) has issued Request for Proposal (RFP) No. 75N95024R00003 for the "Preparation and Distribution of Research Drug Products". The RFP invites proposals from qualified businesses with a submission deadline of November 15, 2024. The resulting contract is expected to incorporate an indefinite delivery, indefinite quantity (IDIQ) structure for a five-year period, allowing for cost reimbursement and/or fixed-price task orders based on NIDA's programmatic needs. Key focuses of the project will be acquiring, analyzing, creating, regulating, and distributing a variety of drug compounds essential for drug abuse research. All offerors are required to maintain active registration in the System for Award Management (SAM) and adhere to federal acquisition regulations. Proposals must be submitted electronically according to the guidelines stated in the attached documentation. Essential reporting and compliance requirements are outlined, ensuring transparency and accountability throughout the contract period. The contract aims to bolster research capabilities addressing drug abuse and addiction through defined deliverables and adherence to protocols involving controlled substances.
    SSN_OTSB_Final.pdf
    The National Institute on Drug Abuse (NIDA) is seeking Capability Statements from Other Than Small Business (OTSB) organizations for the preparation and distribution of research drug products in response to solicitation No. 75N95024R00003, focusing on controlled and uncontrolled drug compounds. This notice aims to assess the availability and capability of potential vendors while gathering information on their qualifications related to the NAICS code 541715. Interested parties must submit relevant documentation by November 16, 2023, specifying their compliance with mandatory requirements and project tasks outlined in the notice.
    Similar Opportunities
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Long Sequencing Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) NIDA, is seeking qualified small businesses to provide Long Sequencing Kits as part of a Sources Sought notice. The primary objective of this procurement is to acquire kits that facilitate long read sequencing for analyzing biomarkers related to Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD), which are crucial for understanding disease progression and therapeutic efficacy. The kits must meet specific technical requirements, including compatibility with Nanopore PromethION 48 sequencers and the ability to generate substantial sequencing data in real-time. Interested parties must submit their capability statements to Andrea Clay at amcgee@nida.nih.gov by December 31, 2024, at 12:00 PM Eastern Time, as this notice is strictly for research and information purposes and does not obligate the government to award a contract.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant (AMR) bacterial and fungal pathogens, and the creation of Direct Acting Antivirals (DAA) targeting viruses of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases, with an estimated funding of $28.5 million available for awards in fiscal year 2026. Proposals for Research Area 001 are due by February 21, 2025, while those for Research Area 002 must be submitted by January 21, 2025. Interested parties can contact Swee L. Teo at teosl@niaid.nih.gov or Brian Madgey at brian.madgey@nih.gov for further information.
    cDNA-PCR Sequencing Kits for long-read sequencing.
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of cDNA-PCR Sequencing Kits for long-read sequencing, as part of a combined synopsis/solicitation. The primary objective is to acquire Promethion Flow Cell packs and sequencing kits to support high-throughput sequencing efforts aimed at advancing research on neurodegenerative diseases, particularly Alzheimer's disease. This procurement is crucial for the Center for Alzheimer’s Disease and Related Dementias (CARD) and is expected to facilitate the identification of causative genes and potential therapeutic targets. Interested vendors must submit their quotations by 5:00 p.m. Eastern Time on December 30, 2024, referencing Solicitation Number 75N95025Q00008, and can direct inquiries to Iris Merscher at iris.merscher@nih.gov or by phone at 301-827-2547.
    In Vitro Assessments of Antimicrobial Activity
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the In Vitro Assessments of Antimicrobial Activity (IVAAA) program through a Multiple Award Indefinite Quantity contract. The primary objective is to provide in vitro testing capabilities to evaluate the therapeutic potential of compounds against over 270 infectious agents, including bacteria, viruses, fungi, and parasites, thereby enhancing public health preparedness and response to infectious diseases. This solicitation is critical for advancing research in the development of vaccines, therapeutics, and diagnostics, with a funding range between $2,500 and $15 million, and proposals are due by March 10, 2025. Interested parties can contact Alexander Beraud at alexander.beraud@nih.gov for further information.
    Pathology Support for the National Institute of Environmental Health Sciences
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for pathology support services for the National Institute of Environmental Health Sciences (NIEHS) under solicitation number 75N96025R00003. The procurement aims to secure comprehensive pathology-related services, including technical support, histopathological evaluations, and assistance with reporting and publication of findings, with a contract period anticipated from July 2025 to July 2026, and options for extensions up to July 2035. This initiative is crucial for enhancing NIEHS's research capabilities while ensuring compliance with federal regulations regarding human subjects and promoting inclusivity in research practices. Interested parties must submit their proposals by 4:00 PM EST on January 6, 2025, and can direct inquiries to Sue McKenzie at sue.mckenzie@nih.gov or Erica Kitzmiller at erica.kitzmiller@nih.gov.
    Assay Kits for Lumipulse instrument
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of assay kits for the Lumipulse instrument, aimed at quantifying specific biomarkers related to Alzheimer's Disease. The acquisition includes a total of 4,410 assays for biomarkers abeta42, abeta40, and pTau 217, which will be utilized in research involving stored samples from the Baltimore Longitudinal Study of Aging (BLSA) to assess cognitive decline and neurodegeneration. This procurement is critical for advancing Alzheimer’s research and will be awarded as a firm fixed-price purchase order, with quotations due by 5:00 p.m. Eastern Time on January 8, 2025. Interested vendors should contact Iris Merscher at iris.merscher@nih.gov for further details.
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY25 Broad Agency Announcement (BAA) aimed at advancing regulatory science and innovation. This opportunity invites organizations, particularly small businesses, to submit research and development proposals that address critical areas such as alternative drug development methods, advanced manufacturing technologies, and predictive toxicology, with a strong emphasis on including diverse populations in research. Proposals must be submitted by February 24, 2025, and will undergo a two-tier evaluation process, with the potential for multiple contracts awarded based on proposal quality and funding availability. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    65--Illumina Reagents and Consumables
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Heart, Lung, and Blood Institute (NHLBI), intends to award a non-competitive contract to Illumina, Inc. for the supply of "Illumina Reagents and Consumables" essential for various sequencing and genotyping systems. This procurement is driven by the unique operational needs of NIH-owned systems, as confirmed by market research indicating that only Illumina can provide the proprietary reagents necessary to maintain research integrity and support ongoing studies. The contract performance period is set from September 3, 2025, to September 2, 2030, and interested parties may submit capability statements for review by January 6, 2025; however, this is not a solicitation for proposals. For further inquiries, interested parties can contact Ethan J. Mueller at ethan.mueller@nih.gov or by phone at +1 301 496 2153.
    Preventative Maintenance and Service Package for the Mediso nanoScan PET/CT animal imager
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), is seeking qualified vendors to provide a Preventative Maintenance and Service Package for the Mediso NanoScan PET/CT animal imager. This procurement involves a comprehensive service plan that includes a 12-month base period followed by four optional 12-month periods, commencing on February 10, 2025, at the Biomedical Research Center in Baltimore, Maryland. The Mediso NanoScan PET/CT is crucial for advanced imaging in biomedical research, and the selected vendor must demonstrate technical capabilities, customer support, and delivery speed as part of the evaluation process. Interested parties should note that the Request for Quotation (RFQ) number is 75N95025Q00104, with responses due by January 6, 2025. For further inquiries, vendors can contact Andrew Varley at andrew.varley@nih.gov or Joshua T. Lazarus at Josh.Lazarus@nih.gov.